Utilization of Antiviral Medications in COVID-19 Patients with Chronic Kidney Disease in Hospital

Yuneka Saristiana; Fendy Prasetyawan; Faisal Akhmal Muslikh; Anis Akhwan Dhafin; Ratna Mildawati; Elsa Mahardika Putri; Susilo Margining Raharjo

doi:10.55927/ijcs.v1i1.7284

Authors

Yuneka Saristiana Universitas Kadiri
Fendy Prasetyawan Universitas Kadiri
Faisal Akhmal Muslikh Institut Ilmu Kesehatan Bhakti Wiyata
Anis Akhwan Dhafin Universitas Kadiri
Ratna Mildawati Stikes Ganesha Husada
Elsa Mahardika Putri Universitas Kadiri
Susilo Margining Raharjo Universitas Kadiri

DOI:

https://doi.org/10.55927/ijcs.v1i1.7284

Keywords:

Covid-19, Antiviral, Medications

Abstract

The COVID-19 pandemic has presented a substantial global health challenge, affecting diverse patient populations, particularly those with chronic kidney disease. Hospitals are presently dependent on two antiviral medications, favipiravir and remdesivir, to mitigate the impact of this disease on patients with chronic kidney disease. This study aims to evaluate the utilization of favipiravir and remdesivir in COVID-19 patients with chronic kidney disease in a hospital setting. This research will employ a retrospective approach to gather data from the medical records of COVID-19 patients with chronic kidney disease who received treatment with favipiravir or remdesivir in the hospital. Considering the prevalence of favipiravir usage at 64% and remdesivir at 36%, this research aims to provide a comprehensive understanding of the effectiveness and associated risks of toxicity linked to these two medications in COVID-19 patients with chronic kidney disease

Downloads

Download data is not yet available.

References

Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., Xia, J., Yu, T., Zhang, X., & Zhang, L. (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet (London, England), 395(10223), 507–513. https://doi.org/10.1016/S0140-6736(20)30211-7.

Di Gennaro, F., Pizzol, D., Marotta, C., Antunes, M., Racalbuto, V., Veronese, N., & Smith, L. (2020). Coronavirus diseases (COVID-19) current status and future perspectives: A narrative review. International Journal of Environmental Research and Public Health, 17(8). https:/ /doi. org/10.3390/ijerph17082690.

Prasetyawan, F., & Saristana, Y. (2023). CORONAVIRUS DESEASE 2019 (COVID-19) DAN PENYAKIT GINJAL KRONIS (PGK): Tinjauan Prevalensi, Faktor Risiko dan Pengobatan Pertama. DEWA Publising.

Rudiansyah, M., Nur’Amin, H. W., Lubis, L., Bandiara, R., Roesli, R. M. A., & Rachmadi, D. (2020). COVID-19 and kidney diseases in Indonesia. Systematic Reviews in Pharmacy, 11(7), 435–442. https:// doi. org/ 10.31838/ srp.2020.7.63

Sherina, T., Andriane, Y., & Achmad, S. (2023). Hubungan Penyakit Ginjal Kronik dengan Derajat Klinis Covid-19 di Ruang Rawat Inap RSUD Al- Ihsan Bandung Tahun 2021. Bandung Conference Series: Medical Science, 3(1), 848–852. https://doi.org/10.29313/bcsms.v3i1.6710.

Yıldırım, M., Akgül, Ö., & Geçer, E. (2022). The Effect of COVID-19 Anxiety on General Health: the Role of COVID-19 Coping. International Journal of Mental Health and Addiction, 20(2), 1110–1121. https:// doi. org/ 10.1007/s11469-020-00429-3.

Zhong, B.-L., Luo, W., Li, H.-M., Zhang, Q.-Q., Liu, X.-G., Li, W.-T., & Li, Y. (2020). Knowledge, attitudes, and practices towards COVID-19 among Chinese residents during the rapid rise period of the COVID-19 outbreak: a quick online cross-sectional survey. International Journal of Biological Sciences, 16(10), 1745–1752. https://doi.org/10.7150/ijbs.45221.